Equities

Jiangsu Kanion Pharmaceutical Co Ltd

600557:SHH

Jiangsu Kanion Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)19.22
  • Today's Change0.150 / 0.79%
  • Shares traded8.13m
  • 1 Year change-33.70%
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jiangsu Kanion Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company provides capsules, oral liquid, granules, electuary, tablets, pills, patch and injections. The Company's products are applied in gynecology, orthopedics, cardiovascular and cerebrovascular, anti-infective, anti-tumor and others. The Company distributes its products mainly within domestic markets.

  • Revenue in CNY (TTM)4.87bn
  • Net income in CNY543.34m
  • Incorporated2000
  • Employees5.44k
  • Location
    Jiangsu Kanion Pharmaceutical Co LtdJiangning Industrial ParkEconomic & Technological Development ZneLIANYUNGANG 222047ChinaCHN
  • Phone+86 51 885521990
  • Fax+86 51 885521990
  • Websitehttps://www.kanion.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhejiang Medicine Co., Ltd.8.04bn425.74m10.26bn6.23k23.781.05--1.280.4470.4478.4110.130.63292.915.571,290,409.002.144.322.755.6831.1636.573.396.281.625.950.081958.72-3.962.59-20.373.3412.650.00
Guobang Pharma Ltd5.28bn616.22m10.44bn4.23k16.951.37--1.981.101.109.4413.610.52312.788.161,247,457.006.0810.367.8614.2422.9127.4911.6315.011.82--0.204718.24-6.4910.28-33.4923.7735.60--
Jiangsu Kanion Pharmaceutical Co., Ltd.4.87bn543.34m11.09bn5.44k20.412.07--2.280.93420.93428.399.220.69153.506.92895,523.307.826.6810.549.4972.5574.0211.3110.282.23--0.0025.5711.884.9423.545.33-1.8735.99
Jinyu Bio-Technology Co Ltd1.58bn282.51m11.67bn1.65k40.262.06--7.380.25880.25881.445.050.23652.061.98956,543.204.094.824.795.6857.9758.7817.2819.913.33--0.004336.414.55-3.3734.63-17.77-12.92-25.56
Joinn Laboratories China Co Ltd2.33bn-62.99m11.70bn2.50k--1.57--5.02-0.0862-0.08623.1210.750.230.69068.14---0.68568.99-0.821911.0739.4646.76-2.9832.013.510.99960.007923.794.7842.20-63.0429.668.2123.46
Jiangxi Tianxin Pharmaceutical Co Ltd1.80bn514.80m11.82bn2.47k22.952.71--6.571.181.184.119.950.362.686.66727,792.6010.31--11.11--39.78--28.63--5.51--0.0551---18.34---23.51------
Liaoning Chengda Biotechnology Co Ltd1.76bn420.34m11.85bn1.73k28.061.22--6.731.011.014.2623.410.17430.70611.611,016,911.004.1610.634.2711.0181.4885.7423.8739.5620.80--0.00231.53-3.584.71-34.75-5.5639.78--
Sansure Biotech Inc1.20bn384.73m11.85bn2.01k31.241.58--9.850.64480.64482.0612.770.13770.82741.41599,646.904.1426.744.6930.9774.8267.4730.0642.017.94--0.058922.40-84.3927.12-81.22121.8964.08--
Data as of May 20 2024. Currency figures normalised to Jiangsu Kanion Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

14.87%Per cent of shares held by top holders
HolderShares% Held
China Investment Corp. (Investment Management)as of 06 Feb 202417.89m3.10%
China Southern Asset Management Co., Ltd.as of 06 Feb 202411.82m2.05%
Essence Fund Co., Ltd.as of 31 Dec 202310.59m1.84%
China Asset Management Co., Ltd.as of 31 Dec 202310.54m1.83%
Caitong Securities Asset Management Co., Ltd.as of 31 Dec 20239.50m1.65%
China Universal Asset Management Co., Ltd.as of 31 Dec 20236.29m1.09%
Da Cheng Fund Management Co., Ltd.as of 06 Feb 20245.29m0.92%
Rongtong Fund Management Co., Ltd.as of 30 Sep 20235.00m0.87%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 20234.70m0.82%
Hotland Innovation Asset Management Co. Ltd.as of 31 Dec 20234.09m0.71%
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.